Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $1,150,023.60 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 261,369 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. The trade was a 13.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Humacyte Stock Performance

Shares of HUMA stock opened at $4.38 on Friday. The stock’s fifty day moving average is $5.36 and its two-hundred day moving average is $6.18. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. Humacyte, Inc. has a fifty-two week low of $2.43 and a fifty-two week high of $9.97.

Institutional Trading of Humacyte

A number of hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC raised its holdings in shares of Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after acquiring an additional 524,600 shares during the period. Virtu Financial LLC purchased a new position in shares of Humacyte in the first quarter valued at approximately $197,000. Vanguard Group Inc. grew its stake in shares of Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after acquiring an additional 896,415 shares in the last quarter. Millennium Management LLC grew its stake in Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Humacyte by 62.7% during the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after buying an additional 97,931 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Humacyte in a research note on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. TD Cowen reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $11.00.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.